Spots Global Cancer Trial Database for Study of RAD001 in Patients With Relapsed/Refractory Hodgkin Lymphoma That Has Progressed After High-dose Chemotherapy and Autologous Stem Cell Transplant and/or After Gemcitabine- or Vinorelbine- or Vinblastine-based Treatment.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Trial Identification
Brief Title: Study of RAD001 in Patients With Relapsed/Refractory Hodgkin Lymphoma That Has Progressed After High-dose Chemotherapy and Autologous Stem Cell Transplant and/or After Gemcitabine- or Vinorelbine- or Vinblastine-based Treatment.
Official Title: An Open-label, Single-arm Phase II Study of RAD001 in Patients With Relapsed/Refractory Classical Hodgkin Lymphoma
Study ID: NCT01022996
Conditions
Interventions
Study Description
Brief Summary: This study will assess RAD001 in patients with refractory or relapsed Hodgkin Lymphoma that has progressed after high-dose chemotherapy and Autologous Stem cell transplant and/or after gemcitabine- or vinorelbine- or vinblastine-based treatment.
Detailed Description:
Keywords
Eligibility
Minimum Age: 18 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: ALL
Healthy Volunteers: No
Locations
University of California at Los Angeles UCLS School of Medicine, Los Angeles, California, United States
Rocky Mountain Cancer Centers RMCC - Aurora, Greenwood Village, Colorado, United States
MD Anderson Cancer Center - Orlando, Orlando, Florida, United States
Emory University School of Medicine/Winship Cancer Institute Emory University Med School, Atlanta, Georgia, United States
Lurie Children's Hospital of Chicago Robert H. Lurie Comp Cancer, Chicago, Illinois, United States
Indiana University Simon Cancer Center, Indianapolis, Indiana, United States
Dana Farber Cancer Institute, Boston, Massachusetts, United States
Karmanos Cancer Institute Karmanos-1, Detroit, Michigan, United States
Mayo Clinic - Rochester Mayo Lymphoma Group, Rochester, Minnesota, United States
Washington University School Of Medicine-Siteman Cancer Ctr StudyCoordinator:CLBH589B2201, St. Louis, Missouri, United States
New York Presbyterian Hospital Weill Cornell Med Ctr, New York, New York, United States
Duke University Medical Center Duke University Medical Ctr, Durham, North Carolina, United States
University of Tennessee Cancer Institute Univ Tennessee Cancer, Memphis, Tennessee, United States
University of Texas/MD Anderson Cancer Center Dept.ofMDAndersonCancerCtr(3), Houston, Texas, United States
University of Wisconsin Comprehensive Cancer Center Clinical Science Center - H4, Madison, Wisconsin, United States
Medical College of Wisconsin, Milwaukee, Wisconsin, United States
Contact Details
Name: Novartis Pharmaceuticals
Affiliation: Novartis Pharmaceuticals
Role: STUDY_DIRECTOR
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
